TG Therapeutics Reports $141.1 Million Revenue in Q2 2025, Driven by BRIUMVI Sales

TG Therapeutics, Inc. reported significant financial growth in its latest quarterly filing, with total revenue reaching $141.1 million for the three months ended June 30, 2025, compared to $73.5 million for the same period in 2024. This increase was primarily driven by product revenue from BRIUMVI, which amounted to $138.8 million, up from $72.6 million year-over-year. For the six-month period ending June 30, 2025, total revenue was $262.0 million, a substantial rise from $136.9 million in the prior year. The company also achieved a net income of $28.2 million for the second quarter, compared to a net income of $6.9 million in the same quarter of the previous year.

The financial performance reflects a notable shift from previous periods, where the company had reported operating losses. The increase in revenue is attributed to greater market penetration of BRIUMVI, which was launched in the U.S. in January 2023 and has since expanded into international markets through partnerships, including a significant agreement with Neuraxpharm for commercialization in Europe. The company has also seen a rise in its accumulated deficit, which stood at approximately $1.5 billion as of June 30, 2025.

Operationally, TG Therapeutics has made strides in expanding its product offerings and market presence. The company is actively developing additional formulations of BRIUMVI, including a subcutaneous version, and has initiated clinical trials for azer-cel, a CAR T-cell therapy targeting autoimmune diseases. As of June 30, 2025, the company reported an increase in its employee headcount, reflecting its ongoing investment in research and development, which totaled $78.1 million for the first half of 2025, compared to $50.3 million in the same period of 2024.

The company’s balance sheet as of June 30, 2025, showed total assets of $702.6 million, up from $577.7 million at the end of 2024. Cash and cash equivalents, along with investment securities, totaled approximately $278.9 million, which the company anticipates will provide sufficient liquidity for its operations over the next twelve months. However, TG Therapeutics acknowledged the potential need for additional financing to support its ongoing and future operations, particularly in light of its significant research and development expenditures.

Looking ahead, TG Therapeutics remains focused on the commercialization of BRIUMVI and the advancement of its clinical pipeline. The company is optimistic about its growth trajectory, driven by the successful launch of BRIUMVI and the potential for additional revenue from new product candidates. However, it also cautioned that future profitability will depend on continued market acceptance of its products and the successful execution of its strategic plans.